Status:
WITHDRAWN
Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema
Lead Sponsor:
Asociación para Evitar la Ceguera en México
Conditions:
Diabetes Mellitus Type 2
Diabetic Macular Edema
Eligibility:
All Genders
45+ years
Phase:
PHASE3
Brief Summary
Intravitreal Bevacizumab is an effective treatment for the diffuse diabetic macular edema
Detailed Description
A non-randomized prospective clinical interventional study which includes 45 non previously treated patients with DME. The patients received a single intravitreal injection of 2.5 mg bevacizumab. Foll...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Macular edema involving the center of the macula demonstrated on OCT
- Clear ocular media
- Untreated patients
- Older than 45 years
- BCVA of the fellow eye at least 20/100
Exclusion
- Renal diabetic disease, uncontrolled hypertension or stroke history
- Other ocular disease
- Ocular surgery excepting uncomplicated phacoemulsification
- History of photocoagulation (panretinal or focal)
- History of another intravitreal treatment (like triamcinolone)
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00417716
Start Date
September 1 2005
End Date
May 1 2006
Last Update
June 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asociación para Evitar la Ceguera en México
Mexico City, Mexico City, Mexico, 04030